Literature DB >> 23499745

Increasing patient preparedness for sacral neuromodulation improves patient reported outcomes despite leaving objective measures of success unchanged.

Farzeen Firoozi1, Bradley Gill, Michael S Ingber, Courtenay K Moore, Raymond R Rackley, Howard B Goldman, Sandip P Vasavada.   

Abstract

PURPOSE: We assessed how a group shared appointment influenced patient preparedness for sacral nerve stimulation for refractory overactive bladder and/or urge urinary incontinence. We also evaluated subjective and objective outcomes.
MATERIALS AND METHODS: Patients considering sacral nerve stimulation were prospectively enrolled and invited to attend a group shared appointment. This 75-minute presentation included a question and answer period with an implanting surgeon and an implanted patient. Control patients received standard office counseling. A patient preparedness questionnaire was completed after the group shared appointment or office counseling. Response to treatment was determined using the postoperative satisfaction questionnaire, Patient Global Impression of Improvement (PGI-I) and voiding diaries.
RESULTS: In our study 36 women with a mean ± SD age of 61 ± 15 years underwent sacral nerve stimulation. There was no significant difference in patient demographics between the 19 women who attended the group shared appointment and the 17 controls. Overall preparedness was greater in the shared appointment group (p = 0.043) with better understanding of the purpose of (p = 0.003) and alternatives to (p = 0.043) sacral nerve stimulation. Significantly more women in the shared appointment group than controls felt completely prepared (78.9% vs 29.4%, p = 0.003) and completely satisfied (78.9% vs 35.3%, p = 0.003) with sacral nerve stimulation as well as very much better (68.4% vs 17.6%, p = 0.002) according to the PGI-I. There was no difference between the groups in the number of women with a 50% or greater symptom reduction on voiding diary.
CONCLUSIONS: Participating in a group shared appointment before sacral nerve stimulation improved patient preparedness and perceived outcomes of treatment, although there was no difference in objective outcomes based on voiding diary.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GSA; QOL; SNS; UUI; appointments and schedules; electric stimulation; group shared appointment; overactive; quality of life; sacral nerve stimulation; urge; urge urinary incontinence; urinary bladder; urinary incontinence

Mesh:

Year:  2013        PMID: 23499745     DOI: 10.1016/j.juro.2013.03.025

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

Review 1.  Does our limited knowledge of the mechanisms of neural stimulation limit its benefits for patients with overactive bladder? ICI-RS 2013.

Authors:  Jerzy B Gajewski; Anthony J Kanai; Linda Cardozo; Youko Ikeda; Irina V Zabbarova
Journal:  Neurourol Urodyn       Date:  2014-05-16       Impact factor: 2.696

2.  "I Wish Someone Had Told Me That Could Happen": A Thematic Analysis of Patients' Unexpected Experiences With End-Stage Kidney Disease Treatment.

Authors:  Nicole DePasquale; Ashley Cabacungan; Patti L Ephraim; LaPricia Lewis-Boyér; Clarissa J Diamantidis; Neil R Powe; L Ebony Boulware
Journal:  J Patient Exp       Date:  2019-09-03

3.  Predicting success after artificial urinary sphincter: which preoperative factors drive patient satisfaction postoperatively?

Authors:  Nathan Chertack; Bradley C Gill; Kenneth W Angermeier; Drogo K Montague; Hadley M Wood
Journal:  Transl Androl Urol       Date:  2017-12

4.  Patient treatment preferences for symptomatic refractory urodynamic idiopathic detrusor overactivity.

Authors:  Christina L Fontaine; Ian Rudd; Mahreen Pakzad; Rizwan Hamid; Jeremy L Ockrim; Tamsin J Greenwell
Journal:  Urol Ann       Date:  2017 Jul-Sep

Review 5.  Update on the management of overactive bladder.

Authors:  Christina Fontaine; Emma Papworth; John Pascoe; Hashim Hashim
Journal:  Ther Adv Urol       Date:  2021-08-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.